An Observational Study of Patients With Dermatologic Disease

Part of paid clinical trials in New York, New York.

Sponsor: Target PharmaSolutions, Inc.
Study ID: NCT07748169
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Alopecia Areata
Atopic Dermatitis
Hidradenitis Suppurativa (HS)
Vitiligo

Eligibility Criteria

Sex: ALL
Age: N/A - N/A
Healthy Volunteers: Not accepted

Study Details

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.

Key Dates

First listed: Aug 5, 2026
Start date: Sep 30, 2026
Status verified: Sep 2026
Primary completion: Aug 3, 2041
Completion: Aug 3, 2041

Study Design

Enrollment: 2,000,000 participants (estimated)

Arms

Arm: Disease Cohort
Adult patients and patients under the age of majority with a diagnosis of DD by ICD or other relevant healthcare code in the EHR interface.
Arm: Engaged Cohort
Adult patients and patients under the age of majority diagnosed and managed for DD invited to participate OR HCPs who treat patients with these conditions. * Informed consent is required for all participants in an Engaged Cohort. * Willing to complete required Engaged Cohort activities.